Dr. David L. Grinblatt
Claim this profileNorthShore University HealthSystem-Evanston Hospital
Area of expertise
Acute Lymphocytic Leukemia
David L. Grinblatt has run 2 trials for Acute Lymphocytic Leukemia. Some of their research focus areas include:
Lymphoma
David L. Grinblatt has run 2 trials for Lymphoma. Some of their research focus areas include:
Affiliated Hospitals
NorthShore University HealthSystem-Evanston Hospital
NorthShore University HealthSystem-Glenbrook Hospital
Clinical Trials David L. Grinblatt is currently running
Novel Therapies
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. "High-risk" refers to traits that have been known to make the AML harder to treat. Cytarabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Daunorubicin is in a class of medications called anthracyclines. It also works by slowing or stopping the growth of cancer cells in the body. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. There is evidence that these newer experimental treatment regimens may work better in getting rid of more AML compared to the standard approach of cytarabine and daunorubicin.
Recruiting
1 award
Phase 2
17 criteria
Lenalidomide + Dexamethasone +/- Daratumumab
for Multiple Myeloma
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.
Recruiting
2 awards
Phase 3
12 criteria
More about David L. Grinblatt
Clinical Trial Related
7 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments David L. Grinblatt has experience with
- Venetoclax
- Cytarabine
- Obinutuzumab
- Dexamethasone
- Ibrutinib
- Daratumumab
Breakdown of trials David L. Grinblatt has run
Acute Lymphocytic Leukemia
Lymphoma
Chronic Lymphocytic Leukemia
Acute Myeloid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David L. Grinblatt specialize in?
David L. Grinblatt focuses on Acute Lymphocytic Leukemia and Lymphoma. In particular, much of their work with Acute Lymphocytic Leukemia has involved 13q positive patients, or patients who are 13q negative.
Is David L. Grinblatt currently recruiting for clinical trials?
Yes, David L. Grinblatt is currently recruiting for 3 clinical trials in Evanston Illinois. If you're interested in participating, you should apply.
Are there any treatments that David L. Grinblatt has studied deeply?
Yes, David L. Grinblatt has studied treatments such as Venetoclax, Cytarabine, Obinutuzumab.
What is the best way to schedule an appointment with David L. Grinblatt?
Apply for one of the trials that David L. Grinblatt is conducting.
What is the office address of David L. Grinblatt?
The office of David L. Grinblatt is located at: NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois 60201 United States. This is the address for their practice at the NorthShore University HealthSystem-Evanston Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.